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Stable DHLA–PEG capped PbS quantum dots:
from synthesis to near-infrared biomedical
imaging†
F. Zamberlan, *ab L. Turyanska, *bc A. Patane`,c Z. Liu,a H. E. L. Williams,a
M. W. Fay, d P. A. Clarke,e Y. Imamura,f T. Jin, f T. D. Bradshaw,g N. R. Thomasa
and A. M. Grabowskae
The short shelf-life of water-soluble quantum dots (QDs) due to
colloidal instability represents a major drawback to their exploita-
tion. This work examines the colloidal stability of PbS nanoparticles
capped with dihydrolipoic acid–polyethylene glycol (DHLA–PEG)
ligands terminated with functional groups such as –NH2, –COOH,
OMe and –N3. and their application for in vivo imaging. We prove
a mechanism of colloidal instability and develop a strategy to
produce for the first time stable PEG-capped PbS quantum dots
with high quantum yield and optical emission in the first and the
second near-infrared (NIR) windows of low absorption of biological
tissues. The NIR imaging of in vivo biodistribution is demonstrated at
wavelengths >1000 nm, with benefits of reduced tissue absorption
and light scattering. The stability, biocompatibility and potential
for further QD functionalization open up realistic prospects for
non-invasive bioimaging applications.
The stability of colloidal nanoparticle solutions in physiological
solvents is a key prerequisite for their applications in bio-
imaging and nanomedicine.1–3 Various nanomaterial systems
have been explored for medical imaging, including metal
nanoparticles,4,5 upconverting nanoparticles6 and semiconduc-
tor quantum dots.7 Of particular interest is the development
of biocompatible colloidal quantum dots (QDs) with optical
emission tuneable in the near-infrared (NIR) wavelength range
of reduced light scattering and low absorption of biological
tissues,8–10 which can be achieved with IV–VI-based semi-
conductor materials (e.g. PbS, PbSe).9,11 The important role of
surface ligands for controlling and designing functional nano-
materials has been widely acknowledged.12,13 It has also been
shown that the efficiency of ligand binding to the surface of
a nanocrystal has a strong influence on QD polydispersity,
quantum yield and photostability.14,15 Polymer-based capping
ligands that are biologically inert, e.g. polyethylene glycol
(PEG),3,16,17 have been successfully used to produce a range
of colloidal nanomaterials, from metal nanoparticles to semi-
conductor QDs.13,16–19 However, the development of capping
ligands that can effectively passivate the surface of a nano-
crystal, provide longevity and colloidal stability, do not alter its
optical properties and allow controllable attachment of func-
tional molecules remains a challenge.13,20 On the other hand,
the modular attachment of PEG to dihydrolipoic acid (DHLA) as
the anchoring moiety of the ligand has been shown to improve
the passivation of nanoparticles, such as AuNP and CdSe–ZnS
QDs.21–24 Despite promising optical and electronic properties,
the technological exploitation of these materials has stalled due
to their short shelf-life caused by colloidal instability.
Here we report the development of nanoparticles that
combine the beneficial biocompatibility and stability oﬀered
by DHLA–PEG-ligands with the tuneability of the emission of
PbS nanocrystals in the NIR wavelength range of low absorption
of biological tissues. We report on the stability of DHLA–PEG
ligands and their utilization for surface passivation of quantum
dots. We investigate the reasons for previously reported colloidal
instability and short shelf-life of colloidal solutions of thiol-
linked, PEG-capped nanoparticles. We report time-dependent
nuclear magnetic resonance (NMR) studies of ligand molecules
and QDs, and suggest a strategy for the synthesis of stable
nanoparticle solutions. The DHLA–PEG ligands, modified with
functional groups including OMe, NH2, COOH and N3,
are used to synthesize colloidal PbS QDs in aqueous solution
with high quantum yield (B30%) and with room temperature
photoluminescence (PL) tuneable by the QD core size in the NIR
wavelength range, hence enabling enhanced light penetration
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through deep tissues and in vivo NIR imaging of QD bio-
distribution in mice. These results open up prospects for use of
PbS–DHLA–PEG QDs in biomedical applications where functional
groups can be used for the controllable attachment of targeting
molecules, such as peptides, small proteins or antibodies.
The ligands used in this work are composed of three parts:
DHLA, a PEG400 linker, and a functional group, R*, such as
OMe, NH2, COOH and N3,22,25 corresponding to ligand
molecules LOMe, LNH2, LCOOH and LN3, respectively. PEG400 is
a hydrophilic molecule that provides water solubility, pH stability
and biocompatibility of the QDs, and can be easily changed for
a diﬀerent chain length from PEG200 to PEG2000. The stability
and aging of ligand molecules has been assessed by NMR time-
course (Fig. 1 and ESI,† SI2). Our 1H-NMR studies indicate that
for the LNH2 and LN3 molecules, the spontaneous oxidation of
the DHLA and reformation of the disulfide bond of its parent
compound lipoic acid (LA) takes place with B70% conversion
over 48 h (Fig. 1a). A clear resurgence of the proton signals at
B2.45 ppm (Hb*) and at B3.18 ppm (Ha*/a0*) (see Fig. 1b) is
observed in LNH2, which are typical of the 5-membered dithio-
lane ring containing the disulfide bond. At the same time, the
intensities of peaks at 2.71 ppm (Ha/a0) and 2.94 ppm (Hc),
characteristic of DHLA, decrease. The change of intensities is
described by the first order kinetic regime with comparable time
constants (inset in Fig. 1b), as expected for the interconversion
reaction where DHLA is oxidized to LA. These results indicate
the inherent instability of LNH2 and LN3, which is likely due to
the interaction between the amine moiety and the thiols.26,27
On the other hand, LOMe and LCOOH are stable and do not
undergo spontaneous oxidation (Fig. 1c and ESI,† SI2) over the
same observation period. The formation of the disulfide bond
prevents the ligand binding to the nanoparticle surface, thus
aﬀecting the colloidal stability of QDs.
Particular attention to the purification of the ligand mixture
is paramount for the stability of aqueous QD solutions. During
the ligand synthesis, the Staudinger reduction uses triphenyl
phosphine (Ph3P), generating triphenylphosphine oxide (Ph3P(O))
as a by-product. The 31P NMR shows a clear peak at 29 ppm,
confirming the presence of Ph3P(O) (ESI,† SI2). The Ph3P(O)/Ph3P
present in the reaction mixture can compete with the DHLA–PEG
as a QD capping molecule, thus altering the aqueous solubility
of the nanocrystals.28
We have used these DHLA–PEG capping ligands to produce
PbS quantum dots either in aqueous solution or in phosphate
buffered saline (PBS) (Fig. 2a) with sizes tuneable by the molar
ratio of Pb : S.29 For the Pb : S ratio of 1 : 0.3, the QDs have average
diameter dPbS = 3.2  0.8 nm (Fig. 2b). The dark field TEM
studies reveal the presence of a thick carbon-based amorphous
layer with non-uniform depth surrounding the PbS nanocrystal.
Fig. 1 (a) Reaction scheme of the oxidation of the dithiols to the dithiolane
ring; R is the remaining part of lipoic acid–PEG400-terminating group.
Representative 1H-NMR spectra of LNH2 (b) and LCOOH (c) for freshly
synthesised ligands and following 48 h storage, with corresponding time
dependence of the intensities of selected resonances.
Fig. 2 (a) Schematic representation of a nanoparticle capped with
DHLA–PEG-based ligands. (b) TEM and (inset) HR TEM images of PbS
QDs synthesized with LNH2 capping ligands and molar ratio Pb : S = 1 : 0.3.
(c) Room temperature photoluminescence (PL) spectra of freshly synthe-
sized (solid line) and 30-days-old (dashed line) PbS QDs (Pb : S = 1 : 0.3).
Inset: Room temperature PL spectrum of PbS QDs with molar ration
of Pb : S = 1 : 0.3, synthesized with a mixture of LNH2 and LCOOH ligands
in 1 : 3 molar ratio.
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The inter-particle distance value ofZ2 nm indicates interlocking
of the DHLA–PEG between neighboring nanocrystals on the
surface.30,31 The average hydrodynamic diameter of the QDs
measured using dynamic light scattering (DLS) is dQD = 11  1 nm,
which is close to our estimate dQD = dPbS + 2l E 13 nm,
where lE 5 nm is the length of the extended ligand molecule.
The QD solutions prepared with molar ratio of Pb : S = 1 : 0.3,
have room temperature photoluminescence centered at lPL =
920 nm, which is independent of the type of ligand and/or
ligand mixture used for surface passivation (Fig. 2c).
By varying the Pb : S ratio from 1 : 0.3 to 1 : 0.6 we produce
quantum dots with a diameter ranging from dPbS E 3.2 nm to
5.5 nm, with corresponding PL emission tuneable in the NIR
range from 920 nm to 1220 nm, respectively (Fig. 3a). The PL
peak position and intensity are comparable for all ligands used,
irrespective of the specific terminating group (OMe, NH2,
COOH and N3) and only small time-dependent shift is
observed due to Ostwald ripening (Fig. 2c). All PbS QD solutions
have quantum yields of about 30% as measured using the
integrated sphere method (Edinburg Instrument spectrometer
FLS980 equipped with 120 mm diameter integrated sphere),
which is higher than that previously reported for other types of
PbS QDs.32 We note that stable colloidal solutions of PbS QDs
can also be produced with mixed ligands, e.g. LNH2 : LCOOH
in a 3 : 1 molar ratio (inset of Fig. 2c). The mixing of the
ligands has a potential benefit for the controlled attachment of
diﬀerent molecules. This in turn could allow greater selectivity,
e.g. attachment of complementary targeting molecules. Also,
the control of the ratio of functional groups on the QD surface
allows tuneability of the surface charge from positive for PbS–
LNH2 (z-potentialB 2.6  3.2 mV) to negative for PbS–LCOOH
QD (z-potential B 41.3  5.5 mV).
The QD solutions prepared using freshly synthesized ligands
have long-term colloidal stability (stored at T = 4 1C under nitrogen
atmosphere) over a period of at least 9 months. 1H-NMR studies
of these QD solutions show a clear resonances at 2.71 ppm
(Ha/a0) and 2.94 ppm (Hc), characteristic for DHLA. In stark
contrast, when ligands were stored prior to the nanocrystal
synthesis, QD solutions precipitated within o10 days and the
1H-NMR spectra of the supernatant confirmed the formation of
the dithiolane ring on the ligand molecules. Hence the instability
is due to lack of surface passivation by the unreactive oxidized
ligand molecules.
The potential of these QDs for bioimaging applications
was assessed by studies of the QD NIR emission penetration
through biological tissues. For these studies we selected the QD
solutions with PL at l > 1000 nm to benefit from low absorption
of biological tissues and lower light scattering, thus achieving
deeper tissue penetration of the emitted light. To account for
the composition of diﬀerent tissues, we prepared mouse brain
and liver tissue slices with thicknesses ranging from t = 0.2 mm
to 4 mm. The slices were placed over two glass capillaries of
diameter d = 1 mm containing PbS–LNH2 solutions with PL
emission of comparable intensity centered at lPL B 1050 nm
(QD1) and at lPL B 1220 nm (QD2) (Fig. 3a). Fig. 3b and c
illustrate representative optical images of 0.5 mm thick brain
and liver slices, respectively, placed over the capillaries. The
corresponding PL maps were acquired at l = 1000  25 nm
Fig. 3 (a) Room temperature PL spectra of PbS–LNH2 nanocrystals QD1 (orange spectrum) and QD2 (red spectrum). The highlighted areas indicate the
wavelength range where PL images through the tissues are acquired. Optical images and corresponding PL images of QD loaded capillary tubes overlaid
with (b) brain and (c) liver tissue slices of thickness t = 0.5 mm. PL images were acquired with excitation wavelength lex = 670 nm and bandpass filters at
(1000  25) nm and at (1300  25) nm. (d) PL intensity measured through the liver tissues versus the tissue thickness at l = 1000 nm and l = 1300 nm.
Dashed lines are guide to the eye.
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(middle images) and at 1300  25 nm (bottom images). They
demonstrate that the NIR fluorescence of the QDs can be
detected through all studied tissues.
However, the observed decrease of light intensity through
tissues is significantly greater for high-blood-content tissues,
such as liver, compared to brain. For example, for brain tissues
of thickness t = 0.5 mm, no measurable decrease of optical
signal was detected compared to capillary only. For the same
thickness of liver tissue, about 5-times decreased intensity was
observed at l = 1000  25 nm and 2-times decreased intensity
at l = 1300  25 nm (Fig. 3d). The use of longer wavelengths
enables better imaging through liver, with B1.5 times higher
resolution achieved for all tissue thicknesses (Fig. 3c and ESI,†
SI3) due to reduced scattering.8,33 We also note that a signal to
noise ratio ofZ3 was achieved for liver tissue of thicknesses up
to 4 mm. The observed signal penetration depth confirms the
suitability of these QDs for non-invasive imaging.
In order to guide the in vivo studies, we assessed the
cytotoxicity of these QDs in vitro by MTT assay. Prior to cell
culture and in vivo studies, we dialyse the QD solutions against
PBS and lower the pH. We note that this process does not alter
the colloidal stability and photostability of the QDs. Previously,
PbS QDs were reported to induce greater toxicity in tumorigenic
cell lines compared to normal cells.29,34 We selected three human
derived carcinoma cell lines: MDA-MB-231 and MCF-7 breast, and
HCT-116 colorectal cells. Assessment after 72 h exposure of cells
to PbS QDs demonstrated that in all three cell lines, neither cell
viability nor cell growth were compromised at PbS QD concentra-
tionsr20 mg mL1 (see ESI,† SI3). The acute toxicity studies over
a period of 30 days have not revealed any QD-induced toxic eﬀects
in mice.34 No indication of damage to the organs/tissues was
found in histological examination of internal organs at the end of
the study, confirming the stability of QDs in vivo and the absence
of release of heavy metal ions from the QDs.
The in vivo biodistribution of QDs was observed using NIR
fluorescence. Mice were injected via tail vein with 30 mL of
0.2 mM PbS QD solution, corresponding to a final concentration
of approximately 10 mg mL1 (2-times lower than the GI50
value). Fig. 4a illustrates typical NIR images (l > 1000 nm) of
PbS QDs (LNH2) in blood vessels in a mouse head immediately
after the injection. The fluorescence in the brain vessels fades
within a few minutes and the emission in not detectable upon
inspection of the brain ex vivo 48 h after injection, indicating
that these QDs do not pass the blood–brain barrier.
Within 1 hour, measurable NIR fluorescence was observed
in the areas of liver and spleen. Fig. 4b illustrates a typical
biodistribution of the PbS QDs, as detected with NIR fluores-
cence 24 hours after the QD injection. The intensities of the
fluorescence signal observed in liver and in spleen are compar-
able when measured in vivo (see top insets in Fig. 4b) and
ex vivo in the corresponding organs (see lower insets of Fig. 4b).
In agreement with our tissue penetration studies, the in vivo
fluorescence intensity is about 2-times lower compared to the
ex vivo value. We note that, as expected, NIR fluorescence was
only detected in QD injected animals (see ESI,† SI3). Following
48 h exposure, the intensity of the optical signal from both liver
and spleen decreased by a factor of B3 compared to that
measured after 24 h exposure. We attribute the observed
decrease of fluorescence to gradual clearance of QDs from the
body. Indeed in some mice, significant fluorescence was
observed in the bladder area, indicating that QDs are cleared
from the body via the urinary tract. There is also some indica-
tion that after 48 h some QDs might be present in lymph nodes,
as was also reported previously.33,35 We exclude the possibility
that the decrease in fluorescence intensity is due to interactions
of QDs with proteins in blood/serum (e.g. with albumin), as we
prepare our QDs with excess ligands to ensure eﬃcient passiva-
tion of the surface in order to eliminate such interactions. Also,
even in the case of QD binding to proteins in serum, the formed
complexes are reported to be both soluble and photostable.36
We note that over the duration of the study, the QDs were
well tolerated by mice. No distress or noticeable physiological
changes were observed. Also, mice organs (liver, spleen, brain,
kidneys, lungs and heart) were inspected after 24 h and after
Fig. 4 (a) Photograph of a mouse head and a corresponding NIR fluorescence image of blood vessels in the head immediately after tail vein injection of
LNH2 capped QDs (PL centred at 1050 nm). (b) Whole body and corresponding intensity surface, and ex vivo NIR fluorescence images of liver (left inset)
and spleen (right inset) of a mouse 24 h after tail vein injection of LNH2 capped QDs (PL centred at 1220 nm). NIR images were acquired with excitation
laser at lex = 670 nm (P = 10 W m
2), InGaAs CMOS camera and a long pass filter at 1000 nm.
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48 h, and no visible morphological changes were observed.
Ex vivo, measurable fluorescence was detected only in spleen
and liver (lower insets in Fig. 4b). Importantly, no noticeable
fluorescence was detected in kidneys, indicating that QDs
do not accumulate and are well cleared via the kidneys. No
noticeable changes in QD biodistribution and in fluorescence
intensity were observed for QDs capped with ligands termi-
nated with diﬀerent functional groups.
In our preliminary studies, we have successfully attached
folic acid and cyclic RGD peptides, as cellular targeting ligands,
using –NH2 and –N3 terminated ligands, respectively, and
produced nanoparticles with these functionalized ligands.
Further work is underway to explore the targeting efficiency
of these functionalized nanocrystals in tumour bearing mice
and to fully assess the potential of these QDs for bioimaging
applications.
Conclusions
In conclusion, we have identified and addressed the causes that
trigger the instability of colloidal nanoparticles capped with
DHLA–PEG-based ligands, i.e. LOMe, LNH2, LN3, LCOOH or
their mixtures. Also, we have successfully used these molecules
to produce stable and biocompatible PbS QDs with optical
emission tuneable in the near-infrared wavelength range. The
QDs are well tolerated by mice in vivo and their emission can be
imaged in the second NIR optical window. Our findings
are transferable to other types of semiconductor and metal
nanoparticles and offer potential for further functionalization
of the nanocrystals for a wide range of biomedical applications.
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